SPL 889
Alternative Names: SPL-889Latest Information Update: 08 Sep 2023
At a glance
- Originator SAJE Pharma
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Glutathione-independent formaldehyde dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 31 Dec 2020 Preclinical trials in Inflammation in USA (IV), prior to December 2020 (SAJE Pharma pipeline, September 2023)
- 31 Dec 2020 Preclinical trials in Inflammation in USA (PO), prior to December 2020 (SAJE Pharma pipeline, September 2023)